Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Open-Label, Parallel-Arm Study to Assess the Absolute Bioavailability of a Single, Fixed Subcutaneous Dose of Aducanumab (BIIB037) in Healthy Subjects Compared to a Single, Weight-Based Intravenous Dose

NCT02782975 is registered in ClinicalTrials.gov with Biogen as lead sponsor.

NCT NCT02782975
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02782975 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Open-Label, Parallel-Arm Study to Assess the Absolute Bioavailability of a Single, Fixed Subcutaneous Dose of Aducanumab (BIIB037) in Healthy Subjects Compared to a Single, Weight-Based Intravenous Dose
Lead sponsor
Biogen
Phase
Phase 1
Overall status
Completed
Start date
May 31, 2016
Completion date
November 30, 2016
Enrollment
28 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer's disease